NanoViricides (NYSE-A:NNVC) announced that its president, Anil Diwan, is presenting at the Spartan Capital Investors Conference on Monday at the Pierre Hotel in New York City.
Dr Diwan’s talk, titled "Revolutionizing Antiviral Treatments," will focus on NanoViricides (NYSE-A:NNVC)' lead drug NV-387, a Phase 2-ready, broad-spectrum antiviral targeting RSV and other viruses.
The global market for these treatments is projected to exceed $10 billion by 2027, according to NanoViricides.